Improving inhaler use for asthma and COPD patients with HEPHAÏ
Official title: Clinical and Medico-economic Study to Validate the Performance of a Digital and Personalized Solution (HEPHAÏ) to Support the Use of Inhaled Treatments for Asthma and COPD
Run by Hephai · NCT06099145 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing an app that helps asthma and COPD patients use their inhalers correctly by giving them real-time feedback on their technique.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 238 (estimated) |
| Sponsor | Hephai Industry-sponsored |
| Locations | 5 sites (Dijon and 4 other locations) |
| Trial ID | NCT06099145 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older with asthma or COPD who are using Innovair® or Trimbow® inhalers and have access to the necessary technology.
✕Probably not a fit
Patients with sensory impairments or cognitive limitations that hinder their ability to use the HEPHAÏ application may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical investigation evaluates the HEPHAÏ solution, an AI-based application designed to enhance the proper use of inhalation devices among patients with asthma and COPD. By allowing patients to film their inhaler usage, the app analyzes their technique in real-time, providing immediate feedback and corrective guidance if errors are detected. The study aims to reduce the frequency of critical errors associated with inhaler use, which can lead to ineffective treatment and increased healthcare costs. The HEPHAÏ solution is intended to be a supportive tool for patients using Innovair® or Trimbow® inhalers.
Why it matters
Potential benefit: If successful, this approach could significantly improve treatment effectiveness and reduce healthcare costs associated with asthma and COPD exacerbations.
How similar studies have gone: While the use of AI in healthcare is growing, this specific application for inhaler use is relatively novel and has not been extensively tested in similar studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient at least 18 years of age * Patient followed in pulmonology for Asthma and/or COPD with implementation and/or follow-up of treatment with Innovair® or Trimbow®, * Patient affiliated to a Social Security scheme, * Patient with a hardware support allowing the operation of HEPHAÏ: smartphone, tablet, desktop or laptop computer with graphical interface, video, sound and a high-speed connection at the place of use. Exclusion Criteria: * Patient previously enrolled in another interventional clinical study, * Adult patients who are subject to a legal protection measure (guardianship, judicial safeguard, psychiatric care or deprived of liberty by judicial or administrative decision), * Patient with at least one sensory, visual or tactile impairment, preventing the correct use of a smartphone, tablet and/or computer or preventing the correct performance of the exercise safely, * Patient with a cognitive impairment, severely limiting their ability to concentrate and thus preventing the correct use of a smartphone, tablet and/or computer, * Patient cared for by a specialized team of education, therapeutic for his asthma or COPD follow-up (e.g. asthma school, asthma referent IDE), * Patient who does not understand French, * Patient with an inhalation chamber prescription associated with their inhalation device prescription.
Where it's running
-
Pitié-Salpêtrière Hospital
Paris, France Recruiting -
Hôpital BICHAT
Paris, France Recruiting -
CHU de Dijon
Dijon, France Not yet recruiting -
Hôpital Arnaud de Villeneuve
Montpellier, France Not yet recruiting -
Hôpital COCHIN
Paris, France Not yet recruiting
Study contacts
- Principal investigator: Capucine Capucine.morelot@aphp.fr, Prof. — Department of Pneumonology, Pitié-Salpêtrière Hospital,
- Study coordinator: Serge Kinkingnehun
- Email: serge@hephai.eu
- Phone: +33 6 61 85 06 77
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using oscillometry and machine learning to identify asthma and COPD patterns
This project will test whether machine learning applied to oscillometry and spirometry data from adults with asthma or COPD can recognize different respiratory patterns.
-
Spacer use with triple inhaler therapy to reduce flare-ups in older adults with COPD or asthma
This study tests whether adding a valved face‑mask spacer to a pMDI triple inhaler can reduce moderate-to-severe exacerbations in people aged 65+ with asthma or COPD who are at high risk.
-
Comparing two ventilation methods in patients with asthma and COPD
This study is testing whether a new way of helping people with asthma or COPD breathe on a ventilator can reduce breathing problems compared to a standard method.
-
Using portable dynamic chest X-ray in the ICU
This study is testing a new portable chest X-ray system in the ICU to see if it can give better pictures of lung movement and function compared to regular X-rays and CT scans for critically ill patients.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.